Apraxia arises from lesion to the regions associated with preparation and planning for the motor act, specifically the supramarginal gyrus of the parietal lobe, Broca's area, and the SMA.
Novartis says Zolgensma is designed to repair the genetic cause of SMA by replacing a patient's abnormal or missing gene to halt progression of the disease.